1089P Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), James Larkin(Trinity College Dublin), C. Lance Cowey(Texas Oncology), Michael Schenker(Sorbonne Université), Barbara Merelli(Ospedale Papa Giovanni XXIII), Melanie Pe Benito(Bristol-Myers Squibb (United States)), Jeffrey S. Weber(NYU Langone Health), Jean‐Jacques Grob(Aix-Marseille Université), Rufina Soomro(Bristol-Myers Squibb (United States)), Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Stéphane Dalle(Hospices Civils de Lyon), Margarita Askelson(Bristol-Myers Squibb (United States)), Helen Gogas(National and Kapodistrian University of Athens), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Anna Maria Di Giacomo(University of Siena), Marcus O. Butler(University of Toronto)
Cited by 9
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k